- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06042335
A Feasibility Study for the DAISe EZ Thrombectomy Device - Pacific
March 11, 2024 updated by: MIVI Neuroscience, Inc.
The study is a prospective, multi-center, single arm, feasibility study that will enroll a maximum of 20 subjects.
A maximum of 5 investigational centers in Australia will participate.
Enrollment is expected to take about 4 months, subject participation will last about 3 months.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Stephanie Cihlar
- Phone Number: 763-227-7833
- Email: scihlar@mivineuroscience.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 years or older.
- Pre-stroke (24 hours prior to stroke onset) independent functional status in activities of daily living with modified Rankin Score 0-2.
- Diagnosis of acute ischemic stroke with study enrollment time < 24 hours from onset of symptoms.
- Disabling stroke defined as a baseline NIHSS > 6.
- Confirmed symptomatic, large vessel occlusion of the intracranial internal carotid artery (ICA), MCA-M1 or MCA-M2.
The following imaging criteria must also be met:
For subjects 0-6hrs onset:
- MRI criterion: volume of diffusion restriction as assessed by automated core volume software ≤50 mL OR
- CT criterion: ASPECTS 6 to 10 on baseline CT or CTA-source images or, computed tomography perfusion (CPT) core as assessed by automated core volume software ≤50 mL.
For subjects 6-24hrs onset:
- ≤20mL ischemic core volume if age >80
- ≤30mL ischemic core volume if age <80 and NIHSS 10-20
- ≤50mL ischemic core volume if age <80 and NIHSS >20
- Signed informed consent from patient or legal representative
Exclusion Criteria:
- Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh hemorrhage on presentation.
- Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic.
- Rapidly improving neurological deficits based on the investigator's clinical judgement.
- Pregnancy; if a woman is of child-bearing potential and urine or serum beta HCG test is positive.
- Severe contrast allergy or absolute contraindication to iodinated contrast.
- Difficult endovascular access, difficult aortic arch or severe neurovascular tortuosity that will result in an inability to deliver endovascular therapy.
- Evidence of dissection in the carotid or target artery for treatment.
- Presence of a carotid artery stenosis or occlusion requiring balloon angioplasty or stenting at time of the procedure.
- Renal failure (on dialysis).
- Severe, sustained hypertension resistant to treatment (SBP >185 mmHg or DBP >110 mmHg).
- Use of warfarin anticoagulation with International Normalized Ratio (INR) > 3.0 at the time of the procedure or any known hemorrhagic or coagulation deficiency.
- Use of a direct thrombin inhibitor within the last 48 hours; partial thromboplastin time (PTT) > 2.0 times the normal prior to procedure.
- Cerebral vasculitis or evidence of active systemic infection.
- Suspicion of aortic dissection, presumed septic embolus or suspicion of bacterial endocarditis.
- Clinical symptoms suggestive of bilateral stroke or occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation).
A severe or fatal comorbid illness that will prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient.
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DAISe EZ
Mechanical thrombectomy utilizing the DAISe Thrombectomy System, consisting of the DAISe Thrombectomy Device and DAISe Delivery Catheter, used with aspiration.
|
DAISe Thrombectomy System for mechanical thrombectomy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Successful revascularization
Time Frame: Peri-Procedural
|
Defined as proportion of subjects with mTICI 2b-3 flow post treatment with the DAISe Thrombectomy Device.
|
Peri-Procedural
|
Symptomatic intracranial hemorrhage (sICH) at 24 hours post-procedure
Time Frame: 24 Hours [window: 12-36 hours] post procedure
|
Defined as proportion of subjects with Symptomatic intracranial haemorrhage (sICH) at 24 hours post-procedure as detected by CT/MRI with clinical deterioration of an NIHSS change of greater than or equal to 4.
|
24 Hours [window: 12-36 hours] post procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2024
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
July 1, 2024
Study Registration Dates
First Submitted
August 25, 2023
First Submitted That Met QC Criteria
September 11, 2023
First Posted (Actual)
September 18, 2023
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 11, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 102699
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Ischemic Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAcute Ischemic Stroke (AIS)United States
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalCompletedIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Anaconda Biomed S.L.Not yet recruitingAcute Ischemic Stroke From Large Vessel Occlusion
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
Clinical Trials on DAISe EZ
-
MIVI Neuroscience, Inc.Recruiting
-
MIVI Neuroscience, Inc.TerminatedStroke, AcuteBelgium
-
MIVI Neuroscience, Inc.Active, not recruitingAcute Ischemic StrokeFrance
-
MIVI Neuroscience, Inc.WithdrawnStroke | Cerebrovascular Disorders | Stroke, Ischemic | Stroke, Acute | Cerebrovascular Accident
-
WellSpan HealthUniversity of PennsylvaniaCompletedDifficult Peripheral IV AccessUnited States
-
Vidacare CorporationCompletedPatients Requiring Urgent Vascular AccessUnited States
-
Vidacare CorporationCompleted
-
Vidacare CorporationCompletedIntraosseous Vascular AccessUnited States
-
Guidant CorporationCompletedSudden Cardiac Death
-
Vidacare CorporationUnknownIntraosseous Access | Infusion Rates | Intraosseous Blood | Venous BloodUnited States